Antios Therapeutics is a biopharmaceutical company devoted to developing innovative therapies for viral diseases. With an experienced and proven leadership team, the company is focused on the development of its lead oral drug candidate for a potentially curative treatment of HBV infections.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/27/18 | $25,000,000 | Series A |
CAM Capital Delos Capital Domain Associates  Fonds de solidarite FTQ Georgia Research Alliance Lumira Ventures Quantum Vista Capital | undisclosed |
| 04/13/21 | $96,000,000 | Series B |
Adage Capital Management Aisling Capital Altium Capital Amzak Capital Management CAM Capital Delos Capital Granite Point Capital Management LifeSci Venture Partners Lumira Capital Pontifax RA Capital Management Soleus Capital | undisclosed |
